MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

NextEdge Admin

13 Nov 2024

2 min 18 sec

Tempus AI, a leader in AI-driven precision medicine, announced a partnership with Flatiron Health, a healthtech innovator focused on oncology solutions, to integrate its genomic testing within Flatiron’s cloud-based OncoEMR® platform through the Molecular Profiling Integration (MPI). This collaboration will streamline access to Tempus’ genomic testing for the 4,200 providers at over 800 community-based cancer care locations in Flatiron’s U.S. network.

Flatiron’s MPI is a two-way integration that enables providers to order and track Tempus tests, with results received directly in the OncoEMR workflow. This system reduces administrative tasks and facilitates more seamless, effective patient care.

“This collaboration advances the integration of Tempus’ molecular profiling tools into daily oncology practice,” said Dr. Ezra Cohen, Tempus' Chief Medical Officer of Oncology. “By leveraging Flatiron’s MPI, we improve oncologists’ access to our tests, supporting more precise patient care.”

Flatiron’s Senior Medical Director, Dr. Stephen Speicher, emphasized the impact on personalized cancer care, stating, “This integration ensures that oncologists across our network can easily access Tempus' test data to enhance treatment precision and improve patient outcomes.”

A notable feature of this integration is a unified order form for all MPI-enabled practices, ensuring consistent workflows. Additionally, providers will have comprehensive access to Tempus’ test suite, including xT, xR, xF/xF+, xG/xG+, Ambry, and xM/xM (NeXT Personal® Dx), as well as several AI-enabled diagnostic add-ons. This partnership represents a major step toward optimized, AI-enhanced oncology care.